

BioInvent has submitted a CTA for a Phase 1/2a trial of BI-1607, a novel anti-FcγRIIB antibody for the treatment of patients with solid tumors

- **BioInvent's pipeline expanding to four drug candidates in five clinical trials**

Lund, Sweden – December 8, 2021 – BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial Application (CTA) for the novel, fully human FcγRIIB-blocking antibody, BI-1607.

BI-1607 targets FcγRIIB but is modified in its Fc region to alter its affinity for Fc receptors. By selectively blocking FcγRIIB, BI-1607 enhances the activity of other therapeutic monoclonal antibodies, whose mechanism-of-action involves depletion of tumors or immune suppressive cells. Understanding the biology of FcR/Fc interactions was essential for generating BI-1607, which has a clearly differentiated profile from BioInvent's lead drug candidate BI-1206.

BioInvent intends to explore the activity of BI-1607 in advanced solid tumors and antibody combinations supported by strong preclinical data.

"We are pleased to have completed this step in the development. BI-1607 is a very promising approach given its ability to enhance anti-cancer immunity and approval of the CTA will expand the BioInvent pipeline to four drug candidates in five clinical trials, further underlining the productivity of our technology platform," said **Martin Welschof, CEO of BioInvent**.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. In addition to BI-1607, the company has three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

Press Release
08 December 2021 08:00:00 CET



For further information, please contact:

Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)

Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

Attachments

[BioInvent has submitted a CTA for a Phase 1/2a trial of BI-1607, a novel anti-FcγRIIB antibody for the treatment of patients with solid tumors](#)